Target type: biologicalprocess
The process in which renal water excretion is decreased. [GOC:mtg_cardio]
Renal water retention, also known as water retention or edema, is a condition where the body retains excess fluid, leading to swelling in various tissues and organs. The kidneys play a crucial role in regulating water balance in the body. The process of renal water retention involves a complex interplay of hormonal and physiological mechanisms. The primary regulator of water reabsorption in the kidneys is antidiuretic hormone (ADH), also known as vasopressin. ADH is released from the posterior pituitary gland in response to increased plasma osmolality (concentration of dissolved substances in the blood) or decreased blood volume. ADH acts on the collecting ducts of the kidneys, promoting water reabsorption back into the bloodstream. This process is achieved by increasing the permeability of the collecting duct walls to water, allowing it to move from the tubular fluid back into the blood. Several factors can contribute to renal water retention, including: 1. **Hormonal imbalances**: a. **Increased ADH secretion**: Conditions such as stress, pain, and certain medications can stimulate ADH release, leading to excessive water reabsorption. b. **Decreased ADH production or resistance**: Conditions such as diabetes insipidus, a disorder characterized by insufficient ADH production or resistance to its effects, can lead to reduced water reabsorption. 2. **Kidney disease**: Damage to the kidneys can impair their ability to filter waste products and regulate water balance. 3. **Heart failure**: The heart's inability to pump blood effectively can lead to fluid buildup in the body, including the kidneys, resulting in water retention. 4. **Liver disease**: The liver plays a role in regulating blood volume and protein synthesis, both of which are essential for fluid balance. Liver disease can disrupt these functions, leading to water retention. 5. **Medications**: Certain medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and some blood pressure medications, can cause water retention as a side effect. 6. **Diet**: A diet high in salt can increase fluid retention, as sodium promotes water retention in the body. 7. **Pregnancy**: During pregnancy, hormonal changes and increased blood volume can contribute to water retention. 8. **Menstrual cycle**: Water retention is common during the premenstrual phase of the menstrual cycle. 9. **Other factors**: Other factors that can contribute to water retention include dehydration, lack of physical activity, and prolonged sitting or standing. Symptoms of renal water retention can range from mild to severe. Mild symptoms may include swelling in the hands, feet, ankles, and face. More severe symptoms can include shortness of breath, weight gain, and high blood pressure. Treatment for renal water retention depends on the underlying cause. In cases of hormonal imbalances, medication to regulate ADH levels may be prescribed. Kidney disease, heart failure, and liver disease require specific treatments to address the underlying conditions. Lifestyle modifications, such as reducing salt intake, increasing physical activity, and drinking plenty of fluids, can also help manage water retention. It is important to consult with a healthcare professional for diagnosis and treatment of renal water retention.'
"
Protein | Definition | Taxonomy |
---|---|---|
Vasopressin V2 receptor | A vasopressin V2 receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P30518] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
clotrimazole | conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes | antiinfective agent; environmental contaminant; xenobiotic | |
itraconazole | piperazines | ||
relcovaptan | relcovaptan: a nonpeptide vasopressin V1 receptor antagonist; structure given in first source | proline derivative | |
opc 21268 | OPC 21268: structure given in first source; vasopressin V1 receptor antagonist | ||
mozavaptan | mozavaptan: aquaretic agent; vasopressin V2 receptor antagonist; structure given in first source | benzamides | aquaretic |
conivaptan | conivaptan : The amide resulting from the formal condensation of 4-[(biphenyl-2-ylcarbonyl)amino]benzoic acid with the benzazepine nitrogen of 2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine. It is an antagonist for two of the three types of arginine vasopressin (AVP) receptors, V1a and V2. It is used as its hydrochloride salt for the treatment of hyponatraemia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). | benzazepine | aquaretic; vasopressin receptor antagonist |
lixivaptan | |||
tolvaptan | benzazepine; benzenedicarboxamide | aquaretic; vasopressin receptor antagonist | |
oxytocin | oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour. Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION. | heterodetic cyclic peptide; peptide hormone | oxytocic; vasodilator agent |
deaminooxytocin | demoxytocin : A heterodetic cyclic peptide that is the synthetic analog of the peptide hormone oxytocin where the free amino group in the half-cystine residue is replaced by hydrogen. The mechanism of action and pharmacological properties of demoxytocin and oxytocin are similar. The drug affects the permeability of the cell membrane, increasing the content of calcium ions in smooth muscle cells, thereby increasing its contraction. It stimulates the contraction of smooth muscles of the uterus, as well as stimulating the contraction of myoepithelial cells of the mammary gland, and enhances the secretion of milk. | heterodetic cyclic peptide | oxytocic |
arginine vasopressin | Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. | vasopressin | cardiovascular drug; hematologic agent; mitogen |
opc 51803 | OPC 51803: a nonpeptide vasopressin V(2)-agonist; structure in first source | ||
quercetin | 7-hydroxyflavonol; pentahydroxyflavone | antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger | |
atosiban | oligopeptide | ||
deamino arginine vasopressin | Deamino Arginine Vasopressin: A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR. | heterodetic cyclic peptide | diagnostic agent; renal agent; vasopressin receptor agonist |
l 372662 | L 372662: structure in first source | ||
way-151932 | WAY-151932: structure in first source | ||
l 371257 | L 371257: structure given in first source | ||
l 368899 | |||
ssr 149415 | |||
gsk221149a | GSK221149A: highly selective oxytocin receptor antagonist; structure in first source | dipeptide | |
epelsiban | epelsiban: structure in first source | dipeptide | |
carbetocin | carbetocin : Oxytocin in which the hydrogen on the phenolic hydroxy group is substituted by methyl, the amino group on the cysteine residue is substituted by hydrogen, and the sulfur of the cysteine residue is replaced by a methylene group. A synthetic carba-analogue of oxytocin, it is used to control bleeding after giving birth. Like oxytocin, it causes contraction of the uterus. | heterodetic cyclic peptide | oxytocic |
vasopressin, 1-deamino-4-val-8-arg- | |||
nitd 609 | NITD 609: an antimalarial and coccidiostat; structure in first source | ||
way 267464 |